Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.

President Donald Trump’s administration announced that Medicare will pay reduced prices for 15 prescription drugs, including commonly used weight-loss and cancer medications. At such a critical moment ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...

New Medicare-negotiated prices for 15 widely used medications take effect in 2027, impacting more than 5 million beneficiaries. Total projected sav ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

With the second round of IRA negotiations having been conducted under the Trump administration, GlobalData life sciences research analyst Cyrus Fan, questions what these two diffe ...

A new round of Medicare drug price negotiations shows the impact of the Inflation Reduction Act while exposing an ongoing political fight over who deserves credit for lowering drug costs. The Trump ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.